{"doi":"10.3310/pnxb5040","title":"Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT","abstract":"Background Anti-neutrophil cytoplasm antibody-associated vasculitis is a multisystem, autoimmune disease that causes organ failure and death. Physical removal of pathogenic autoantibodies by plasma exchange is recommended for severe presentations, along with high-dose glucocorticoids, but glucocorticoid toxicity contributes to morbidity and mortality. The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes. Objectives We aimed to determine the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis. We also aimed to determine whether or not a reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen with respect to death and end-stage renal disease. Design This was an international, multicentre, open-label, randomised controlled trial. Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen. All patients received immunosuppressive induction therapy with cyclophosphamide or rituximab. Setting Ninety-five hospitals in Europe, North America, Australia/New Zealand and Japan participated. Participants Participants were aged ≥ 16 years with a diagnosis of granulomatosis with polyangiitis or microscopic polyangiitis, and either proteinase 3 anti-neutrophil cytoplasm antibody or myeloperoxidase anti-neutrophil cytoplasm antibody positivity, and a glomerular filtration rate of < 50 ml/minute/1.73 m 2 or diffuse alveolar haemorrhage attributable to active anti-neutrophil cytoplasm antibody-associated vasculitis. Interventions Participants received seven sessions of plasma exchange within 14 days or no plasma exchange. Oral glucocorticoids commenced with prednisolone 1 mg/kg/day and were reduced over different lengths of time to 5 mg/kg/day, such that cumulative oral glucocorticoid exposure in the first 6 months was 50% lower in patients allocated to the reduced-dose regimen than in those allocated to the standard-dose regimen. All patients received the same glucocorticoid dosing from 6 to 12 months. Subsequent dosing was at the discretion of the treating physician. Primary outcome The primary outcome was a composite of all-cause mortality and end-stage renal disease at a common close-out when the last patient had completed 10 months in the trial. Results The study recruited 704 patients from June 2010 to September 2016. Ninety-nine patients died and 138 developed end-stage renal disease, with the primary end point occurring in 209 out of 704 (29.7%) patients: 100 out of 352 (28%) in the plasma exchange group and 109 out of 352 (31%) in the no plasma exchange group (adjusted hazard ratio 0.86, 95% confidence interval 0.65 to 1.13; p = 0.3). In the per-protocol analysis for the non-inferiority glucocorticoid comparison, the primary end point occurred in 92 out of 330 (28%) patients in the reduced-dose group and 83 out of 325 (26%) patients in the standard-dose group (partial-adjusted risk difference 0.023, 95% confidence interval 0.034 to 0.08; p = 0.5), thus meeting our non-inferiority hypothesis. Serious infections in the first year occurred in 96 out of 353 (27%) patients in the reduced-dose group and in 116 out of 351 (33%) patients in the standard-dose group. The rate of serious infections at 1 year was lower in the reduced-dose group than in the standard-dose group (incidence rate ratio 0.69, 95% confidence interval 0.52 to 0.93; p = 0.016). Conclusions Plasma exchange did not prolong the time to death and/or end-stage renal disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis with severe renal or pulmonary involvement. A reduced-dose glucocorticoid regimen was non-inferior to ","journal":"Health Technology Assessment","year":2022,"id":264492,"datarank":0.5857720853240527,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.20102968170482216,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.20102968170482216,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":12,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9501,"is_data_producer":true,"deposit_databanks":{"ISRCTN":["ISRCTN07757494"],"ClinicalTrials.gov":["NCT00987389"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":107967,"name":"Michael Walsh","orcid":"0000-0001-8292-2014","position":1,"is_corresponding":false},{"id":5969,"name":"Peter A. Merkel","orcid":"0000-0001-9284-7345","position":2,"is_corresponding":false},{"id":107968,"name":"Chen Au Peh","orcid":"0000-0002-9712-0396","position":3,"is_corresponding":false},{"id":107969,"name":"Wladimir Szpirt","orcid":"0000-0002-6570-6077","position":4,"is_corresponding":false},{"id":107970,"name":"Xavier Puéchal","orcid":"0000-0003-3573-9203","position":5,"is_corresponding":false},{"id":107971,"name":"Shouichi Fujimoto","orcid":"0000-0003-2854-8169","position":6,"is_corresponding":false},{"id":107972,"name":"Carmel M. Hawley","orcid":"0000-0002-1392-5649","position":7,"is_corresponding":false},{"id":107973,"name":"Nader Khalidi","orcid":"0000-0002-8270-2617","position":8,"is_corresponding":false},{"id":251765,"name":"Rachel Jones","orcid":"0000-0003-4790-283X","position":9,"is_corresponding":false},{"id":107974,"name":"Oliver Floßmann","orcid":"0000-0001-5976-3609","position":10,"is_corresponding":false},{"id":107975,"name":"Ron Wald","orcid":"0000-0003-4411-8169","position":11,"is_corresponding":false},{"id":107976,"name":"Louis Girard","orcid":"0000-0002-9044-008X","position":12,"is_corresponding":false},{"id":12726,"name":"Adeera Levin","orcid":"0000-0003-2438-8401","position":13,"is_corresponding":false},{"id":922560,"name":"Gina Gregorini","orcid":"0000-0002-8404-3862","position":14,"is_corresponding":false},{"id":107978,"name":"Lorraine Harper","orcid":"0000-0003-1343-9234","position":15,"is_corresponding":false},{"id":107979,"name":"William F. Clark","orcid":"0000-0003-3294-739X","position":16,"is_corresponding":false},{"id":251779,"name":"Christian Pagnoux","orcid":"0000-0001-6287-9549","position":17,"is_corresponding":false},{"id":25214,"name":"Ulrich Specks","orcid":"0000-0002-6559-1206","position":18,"is_corresponding":false},{"id":107981,"name":"Lucy Smyth","orcid":"0000-0001-6814-4877","position":19,"is_corresponding":false},{"id":107982,"name":"Toshiko Ito‐Ihara","orcid":"0000-0001-7152-3026","position":20,"is_corresponding":false},{"id":107983,"name":"Janak de Zoysa","orcid":"0000-0001-7528-9230","position":21,"is_corresponding":false},{"id":107987,"name":"Biljana Brezina","orcid":"0000-0001-5060-5604","position":22,"is_corresponding":false},{"id":107988,"name":"Andrea Mazzetti","orcid":"0000-0002-8889-092X","position":23,"is_corresponding":false},{"id":107989,"name":"Carol A. McAlear","orcid":"0000-0002-0016-6866","position":24,"is_corresponding":false},{"id":107991,"name":"Donna Reidlinger","orcid":"0000-0002-3365-9923","position":25,"is_corresponding":false},{"id":107992,"name":"Samir Mehta","orcid":"0000-0001-7096-513X","position":26,"is_corresponding":false},{"id":107993,"name":"Natalie Ives","orcid":"0000-0002-1664-7541","position":27,"is_corresponding":false},{"id":922561,"name":"Elizabeth Brettell","orcid":"0000-0002-0669-3085","position":28,"is_corresponding":false},{"id":922562,"name":"Hugh Jarrett","orcid":"0000-0001-7374-3700","position":29,"is_corresponding":false},{"id":917773,"name":"Keith Wheatley","orcid":"0000-0003-0792-580X","position":30,"is_corresponding":false},{"id":107990,"name":"Elizabeth Broadhurst","orcid":"0000-0001-8464-4353","position":31,"is_corresponding":false},{"id":922563,"name":"Alina Casian","orcid":"0000-0001-5822-593X","position":32,"is_corresponding":false},{"id":25211,"name":"Charles D. Pusey","orcid":"0000-0002-1424-3906","position":33,"is_corresponding":false},{"id":25203,"name":"David Jayne","orcid":"0000-0002-1712-0637","position":0,"is_corresponding":true}],"reference_count":44,"raw_metadata":null,"created_at":"2026-07-19T00:26:41.845195Z","pmid":"36155131","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}